Dr Ming Hong Shen

2021

• Xie, J. et al. 2021. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. Cellular and Molecular Life Sciences 78(1), pp. 249–270. (10.1007/s00018-020-03491-1)

2020

• Sun, C. et al. 2020. Gallium nitride: a versatile compound semiconductor as novel piezoelectric film for acoustic tweezer in manipulation of cancer cells. IEEE Transactions on Electron Devices 67(8), pp. 3355-3361. (10.1109/TED.2020.3002498)

2019

• Jones, A. T., Yang, J., Narov, K., Henske, E. P., Sampson, J. R. and Shen, M. H. 2019. Allosteric and ATP-competitive inhibitors of mTOR effectively suppress tumor progression-associated epithelial-mesenchymal transition in the kidneys of Tsc2+/− Mice. Neoplasia 21(8), pp. 731-739. (10.1016/j.neo.2019.05.003)
• Jones, A. T., Narov, K., Yang, J., Sampson, J. R. and Shen, M. H. 2019. Efficacy of dual inhibition of glycolysis and glutaminolysis for therapy of renal lesions in Tsc2+/− Mice1. NEOPLASIA 21(2), pp. 230-238. (10.1016/j.neo.2018.12.003)

2018

• Johnson, C. E. et al. 2018. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir−bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. Oncogene 37, pp. 5913-5925. (10.1038/s41388-018-0381-2)

2017

• Shen, M., Samsel, P., Shen, L. L., Narov, K., Yang, J. and Sampson, J. 2017. Assessment of response of kidney tumours to rapamycin and atorvastatin in Tsc1+/- mice. Translational Oncology 10(5), pp. 793-799. (10.1016/j.tranon.2017.07.009)
• Narov, K., Yang, J., Samsel, P., Jones, A., Sampson, J. R. and Shen, M. H. 2017. The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+/- mice through suppression of cell proliferation and induction of apoptosis. Oncotarget, article number: 17215. (10.18632/oncotarget.17215)
• Yang, J. et al. 2017. Combination of everolimus with sorafenib for solid renal tumours in Tsc2+/- mice is superior to everolimus alone. Neoplasia 19(2), pp. 112-120. (10.1016/j.neo.2016.12.008)

2015

• Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R. and Tee, A. R. 2015. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34(17), pp. 2239-2250. (10.1038/onc.2014.164)
• Yang, J. et al. 2015. Renal tumours in a Tsc2+/- mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin. Oncogene 34, pp. 922-931. (10.1038/onc.2014.17)

2013

• Yang, J., Kalogerou, M., Gallacher, J., Sampson, J. and Shen, M. 2013. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. European Journal of Cancer 49(6), pp. 1479-1490. (10.1016/j.ejca.2012.10.027)

2012

• Kalogerou, M. et al. 2012. T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis. European Journal of Radiology 81(9), pp. 2069-2074. (10.1016/j.ejrad.2011.06.054)

2007

• Shen, M. H., Mantripragada, K. K., Dumanski, J. P., Frayling, I. M. and Upadhyaya, M. 2007. Detection of copy number changes at the NF1 locus with improved high-resolution array CGH. Clinical Genetics 72(3), pp. 238-244. (10.1111/j.1399-0004.2007.00858.x)

2006

• Shen, M. H., Mantripragada, K. K., Dumanski, J., Frayling, I. and Upadhyaya, M. 2006. DNA microarray for detection of copy number changes at the NF1 locus using array comparative genomic hybridisation (CGH) analysis [Abstract]. Journal of Medical Genetics 43(Supp.), pp. S19.

1999

• Shen, M. H. 1999. Neurofibromatosis type 1. In: Kurzrock, R. and Talpaz, M. eds. Molecular biology in cancer medicine, 2nd ed.. London: Martin Dunitz, pp. 493-514.